1
|
Arango BA, Castrellon AB, Perez CA, Raez
LE and Santos ES: Nasopharyngeal carcinoma: Alternative treatment
options after disease progression. Expert Rev Anticancer Ther.
10:377–386. 2010. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Yu MC and Yuan JM: Epidemiology of
nasopharyngeal carcinoma. Semin Cancer Biol. 12:421–429. 2002.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Chan AT, Teo PM and Johnson PJ:
Nasopharyngeal carcinoma. Ann Oncol. 13:1007–1015. 2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Yip TT, Ngan RK, Fong AH and Law SC:
Application of circulating plasma/serum EBV DNA in the clinical
management of nasopharyngeal carcinoma. Oral Oncol. 50:527–538.
2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Chan AT, Grégoire V, Lefebvre JL, Licitra
L, Hui EP, Leung SF and Felip E; EHNS–ESMO–ESTRO Guidelines Working
Group: Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
23(Suppl 7): vii83–vii85. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu
LZ, Sun Y, Lin AH, Liu MZ and Ma J: How does intensity-modulated
radiotherapy versus conventional two-dimensional radiotherapy
influence the treatment results in nasopharyngeal carcinoma
patients? Int J Radiat Oncol Biol Phys. 80:661–668. 2011.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Zhang P, Hong H, Sun X, Jiang H, Ma S,
Zhao S, Zhang M, Wang Z, Jiang C and Liu H: MicroRNA-10b regulates
epithelial-mesenchymal transition by modulating
KLF4/Notch1/E-cadherin in cisplatin-resistant nasopharyngeal
carcinoma cells. Am J Cancer Res. 6:141–156. 2016.PubMed/NCBI
|
8
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
9
|
Mack GS: MicroRNA gets down to business.
Nat Biotechnol. 25:631–638. 2007. View Article : Google Scholar : PubMed/NCBI
|
10
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Kim NH, Cha YH, Kang SE, Lee Y, Lee I, Cha
SY, Ryu JK, Na JM, Park C, Yoon HG, et al: p53 regulates nuclear
GSK-3 levels through miR-34-mediated Axin2 suppression in
colorectal cancer cells. Cell Cycle. 12:1578–1587. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Xu J, Ai Q, Cao H and Liu Q: miR-185-3p
and miR-324-3p predict radiosensitivity of nasopharyngeal carcinoma
and modulate cancer cell growth and apoptosis by targeting SMAD7.
Med Sci Monit. 21:2828–2836. 2015. View Article : Google Scholar : PubMed/NCBI
|
14
|
Shan Y, Li X, You B, Shi S, Zhang Q and
You Y: MicroRNA-338 inhibits migration and proliferation by
targeting hypoxia-induced factor 1α in nasopharyngeal carcinoma.
Oncol Rep. 34:1943–1952. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Nie G, Duan H, Li X, Yu Z, Luo L, Lu R, Ji
Z and Zhang W: MicroRNA205 promotes the tumorigenesis of
nasopharyngeal carcinoma through targeting tumor protein
p53-inducible nuclear protein 1. Mol Med Rep. 12:5715–5722. 2015.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Ann Biol Clin (Paris).
68:263–272. 2010.(In French). PubMed/NCBI
|
17
|
Wu D, Niu X, Pan H, Zhou Y, Zhang Z, Qu P
and Zhou J: Tumor-suppressing effects of microRNA-429 in human
renal cell carcinoma via the downregulation of Sp1. Oncol Lett.
12:2906–2911. 2016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Savad S, Mehdipour P, Miryounesi M,
Shirkoohi R, Fereidooni F, Mansouri F and Modarressi MH: Expression
analysis of miR-21, miR-205, and miR-342 in breast cancer in Iran.
Asian Pac J Cancer Prev. 13:873–877. 2012. View Article : Google Scholar : PubMed/NCBI
|
19
|
He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R
and Tang JH: miR-342 is associated with estrogen receptor-alpha
expression and response to tamoxifen in breast cancer. Exp Ther
Med. 5:813–818. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Ma T, Zhang J, Wu J and Tang J: Effect of
miR-342-3p on chemotherapy sensitivity in triple-negative breast
cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 39:488–495. 2014.(In
Chinese). PubMed/NCBI
|
21
|
Li XR, Chu HJ, Lv T, Wang L, Kong SF and
Dai SZ: miR-342-3p suppresses proliferation, migration and invasion
by targeting FOXM1 in human cervical cancer. FEBS Lett.
588:3298–3307. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Xie X, Liu H, Wang M, Ding F, Xiao H, Hu
F, Hu R and Mei J: miR-342-3p targets RAP2B to suppress
proliferation and invasion of non-small cell lung cancer cells.
Tumour Biol. 36:5031–5038. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Xu H, Cai T, Carmona GN, Abuhatzira L and
Notkins AL: Small cell lung cancer growth is inhibited by miR-342
through its effect of the target gene IA-2. J Transl Med.
14:2782016. View Article : Google Scholar : PubMed/NCBI
|
24
|
OuYang PY, Su Z, Ma XH, Mao YP, Liu MZ and
Xie FY: Comparison of TNM staging systems for nasopharyngeal
carcinoma, and proposal of a new staging system. Br J Cancer.
109:2987–2997. 2013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Kenney PA, Wszolek MF, Rieger-Christ KM,
Neto BS, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling
DS, et al: Novel ZEB1 expression in bladder tumorigenesis. BJU Int.
107:656–663. 2011. View Article : Google Scholar : PubMed/NCBI
|
27
|
Jia B, Liu H, Kong Q and Li B:
Overexpression of ZEB1 associated with metastasis and invasion in
patients with gastric carcinoma. Mol Cell Biochem. 366:223–229.
2012. View Article : Google Scholar : PubMed/NCBI
|
28
|
Liu Z, Sun B, Qi L, Li H, Gao J and Leng
X: Zinc finger E-box binding homeobox 1 promotes vasculogenic
mimicry in colorectal cancer through induction of
epithelial-to-mesenchymal transition. Cancer Sci. 103:813–820.
2012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Quan Y, Jin R, Huang A, Zhao H, Feng B,
Zang L and Zheng M: Downregulation of GRHL2 inhibits the
proliferation of colorectal cancer cells by targeting ZEB1. Cancer
Biol Ther. 15:878–887. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zhang G, An H and Fang X: MicroRNA-144
regulates proliferation, invasion, and apoptosis of cells in
malignant solitary pulmonary nodule via zinc finger E-box-binding
homeobox 1. Int J Clin Exp Pathol. 8:5960–5967. 2015.PubMed/NCBI
|
31
|
Wang H, Wu J, Meng X, Ying X, Zuo Y, Liu
R, Pan Z, Kang T and Huang W: MicroRNA-342 inhibits colorectal
cancer cell proliferation and invasion by directly targeting DNA
methyltransferase 1. Carcinogenesis. 32:1033–1042. 2011. View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhao L and Zhang Y: miR-342-3p affects
hepatocellular carcinoma cell proliferation via regulating NF-κB
pathway. Biochem Biophys Res Commun. 457:370–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
33
|
Ronchetti D, Lionetti M, Mosca L, Agnelli
L, Andronache A, Fabris S, Deliliers GL and Neri A: An integrative
genomic approach reveals coordinated expression of intronic
miR-335, miR-342, and miR-561 with deregulated host genes in
multiple myeloma. BMC Med Genomics. 1:372008. View Article : Google Scholar : PubMed/NCBI
|
34
|
Shen A, Zhang Y, Yang H, Xu R and Huang G:
Overexpression of ZEB1 relates to metastasis and invasion in
osteosarcoma. J Surg Oncol. 105:830–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
35
|
Zhang GJ, Zhou T, Tian HP, Liu ZL and Xia
SS: High expression of ZEB1 correlates with liver metastasis and
poor prognosis in colorectal cancer. Oncol Lett. 5:564–568. 2013.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Zhang Y, Liu G, Wu S, Jiang F, Xie J and
Wang Y: Zinc finger E-box-binding homeobox 1: Its clinical
significance and functional role in human thyroid cancer. Onco
Targets Ther. 9:1303–1310. 2016.PubMed/NCBI
|
37
|
Ma Y, Zheng X, Zhou J, Zhang Y and Chen K:
ZEB1 promotes the progression and metastasis of cervical squamous
cell carcinoma via the promotion of epithelial-mesenchymal
transition. Int J Clin Exp Pathol. 8:11258–11267. 2015.PubMed/NCBI
|
38
|
Ning Z, Wu K, Fan J, Wang B, Lv C, Zhu J,
Wang X, Hsieh JT and He D: Aberrant expressions of β-catenin and
ZEB1 in bladder cancer and their significance. Xi Bao Yu Fen Zi
Mian Yi Xue Za Zhi. 30:1080–1083. 2014.(In Chinese). PubMed/NCBI
|
39
|
Chen G, Huang P, Xie J and Li R:
microRNA211 suppresses the growth and metastasis of cervical cancer
by directly targeting ZEB1. Mol Med Rep. 17:1275–1282.
2018.PubMed/NCBI
|
40
|
Wu G, Wang J, Chen G and Zhao X:
microRNA-204 modulates chemosensitivity and apoptosis of prostate
cancer cells by targeting zinc-finger E-box-binding homeobox 1
(ZEB1). Am J Transl Res. 9:3599–3610. 2017.PubMed/NCBI
|
41
|
Zou J, Liu L, Wang Q, Yin F, Yang Z, Zhang
W and Li L: Downregulation of miR-429 contributes to the
development of drug resistance in epithelial ovarian cancer by
targeting ZEB1. Am J Transl Res. 9:1357–1368. 2017.PubMed/NCBI
|
42
|
Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu
Z, Liu T and Hu F: Downregulation of miR429 and inhibition of cell
migration and invasion in nasopharyngeal carcinoma. Mol Med Rep.
13:3236–3242. 2016. View Article : Google Scholar : PubMed/NCBI
|